

Resource Summary Report

Generated by [dkNET](#) on Aug 6, 2026

CD34 Monoclonal Antibody (4H11), APC, eBioscience

RRID:AB_2016672

Type: Antibody

Proper Citation

(Thermo Fisher Scientific Cat# 17-0349-42, RRID:AB_2016672)

Antibody Information

URL: http://antibodyregistry.org/AB_2016672

Proper Citation: (Thermo Fisher Scientific Cat# 17-0349-42, RRID:AB_2016672)

Target Antigen: CD34

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow
Consolidation on 1/2020: AB_2016672, AB_10522922

Antibody Name: CD34 Monoclonal Antibody (4H11), APC, eBioscience

Description: This monoclonal targets CD34

Target Organism: human

Clone ID: Clone 4H11

Antibody ID: AB_2016672

Vendor: Thermo Fisher Scientific

Catalog Number: 17-0349-42

Record Creation Time: 20251213T073830+0000

Record Last Update: 20260225T231018+0000

Ratings and Alerts

No rating or validation information has been found for CD34 Monoclonal Antibody (4H11), APC, eBioscience.

No alerts have been found for CD34 Monoclonal Antibody (4H11), APC, eBioscience.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Abrantes R, et al. (2025) Pan-carcinoma sialyl-Tn-targeting expands CAR therapy to solid tumors. Cell reports. Medicine, 6(9), 102350.

Huang S, et al. (2025) Low-intensity-pulsed-ultrasound-treated menstrual-blood-derived mesenchymal stem cells repair endometrial injury by PI3K/AKT pathway inhibition. Reproductive biomedicine online, 50(3), 104486.

Caulier B, et al. (2024) CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia. Cell reports. Medicine, 5(6), 101572.

Xia L, et al. (2024) Osimertinib Covalently Binds to CD34 and Eliminates Myeloid Leukemia Stem/Progenitor Cells. Cancer research, 84(3), 479.

Du C, et al. (2022) Renal Klotho and inorganic phosphate are extrinsic factors that antagonistically regulate hematopoietic stem cell maintenance. Cell reports, 38(7), 110392.

Wu A, et al. (2022) Multiple gene knockdown strategies for investigating the properties of human leukemia stem cells and exploring new therapies. Methods in cell biology, 171, 1.

Rothe K, et al. (2020) Integrin-Linked Kinase Mediates Therapeutic Resistance of Quiescent CML Stem Cells to Tyrosine Kinase Inhibitors. Cell stem cell, 27(1), 110.

Martin RM, et al. (2019) Highly Efficient and Marker-free Genome Editing of Human Pluripotent Stem Cells by CRISPR-Cas9 RNP and AAV6 Donor-Mediated Homologous Recombination. Cell stem cell, 24(5), 821.

Böiers C, et al. (2018) A Human IPS Model Implicates Embryonic B-Myeloid Fate Restriction as Developmental Susceptibility to B Acute Lymphoblastic Leukemia-Associated ETV6-RUNX1. Developmental cell, 44(3), 362.